ASS1 and colorectal carcinoma: Through computational drug screening, we identified Salvianolic acid B (Sal B) as a potent ZFPL1 inhibitor, and subsequent experimental validation confirmed its ability to disrupt ZFPL1‐ASS1 interaction and suppress CRC malignancy.